Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
17 April 2024 - 6:06AM
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular
Therapies”), a biopharmaceutical company focused on the development
and commercialization of therapeutics for central nervous system
(CNS) disorders, today announced that it has commenced an
underwritten public offering of $500 million of shares of its
common stock. In connection with the offering, Intra-Cellular
Therapies intends to grant the underwriters a 30-day option to
purchase up to an additional 15% of the shares of common stock
offered in the public offering. All of the shares in the offering
will be sold by Intra-Cellular Therapies.
J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley
and RBC Capital Markets are acting as joint book-running managers
for the offering. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
The public offering will be made pursuant to a shelf
registration statement on Form S-3 (including a base prospectus)
that was filed today with the Securities and Exchange Commission
(the “SEC”) and became effective upon filing. A preliminary
prospectus supplement relating to and describing the terms of the
offering will be filed with the SEC and will be available on the
SEC’s website located at http://www.sec.gov. The offering is
being made only by means of a prospectus and related prospectus
supplement, copies of which may be obtained from J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, by telephone at
1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com;
Leerink Partners LLC, Attention: Syndicate Department, 53 State
Street, 40th Floor, Boston, MA 02109, (800) 808-7525 ext. 6105,
syndicate@leerink.com; BofA Securities, Inc., NC1-022-02-25, 201
North Tryon Street, Charlotte, NC, 28255-0001, Attn: Prospectus
Department, Email: dg.prospectus_requests@bofa.com; Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, NY 10014, by email:
prospectus@morganstanley.com; or RBC Capital Markets, LLC,
Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New
York, NY 10281, by telephone at (877) 822-4089, or by emailing
equityprospectus@rbccm.com. The final terms of the offering will be
disclosed in a final prospectus supplement to be filed with the
SEC.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or other jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded
on Nobel prize-winning research that allows us to understand how
therapies affect the inner-workings of cells in the body. The
company leverages this intracellular approach to develop innovative
treatments for people living with complex psychiatric and
neurologic diseases.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements, other than
statements of historical fact, regarding, among other things, the
proposed public offering of common stock. Intra-Cellular Therapies
often uses words such as “anticipates,” “believes,” “plans,”
“expects,” “projects,” “future,” “intends,” “may,” “will,”
“should,” “could,” “estimates,” “predicts,” “potential,” “planned,”
“continue,” “guidance,” and similar expressions to identify
forward-looking statements. Actual results, performance or
experience may differ materially from those expressed or implied by
any forward-looking statement as a result of various risks,
uncertainties and other factors, including, but not limited to:
uncertainties related to market conditions and the completion of
the public offering on the anticipated terms or at all, and other
risks and uncertainties that are described under the heading “Risk
Factors” in Intra-Cellular Therapies’ preliminary prospectus
supplement to be filed with the SEC, Intra-Cellular Therapies’ most
recent Annual Report on Form 10-K or in subsequent filings that it
makes with the Securities and Exchange Commission. As a result of
risks and uncertainties that Intra-Cellular Therapies faces, the
results or events indicated by any forward-looking statement may
not occur. Intra-Cellular Therapies cautions you not to place undue
reliance on any forward-looking statement. In addition, any
forward-looking statement in this press release represents
Intra-Cellular Therapies’ views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. Intra-Cellular Therapies disclaims any
obligation to update any forward-looking statement, except as
required by applicable law.
Contact
Intra-Cellular Therapies, Inc.Juan Sanchez, M.D.Vice President,
Corporate Communications and Investor Relations646-440-9333
Media Inquiries:
Burns McClellan, Inc.Cameron
Radinoviccradinovic@burnsmc.com212-213-0006
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2024 to May 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From May 2023 to May 2024